Nilotinib (Tasigna) versus imatinib (Gleevec) for newly diagnosed, previously untreated chronic myelogenous leukemia (Early Chronic Phase)

Research output: Contribution to journalArticle

Original languageEnglish (US)
Number of pages1
JournalP and T
Volume34
Issue number2
Publication statusPublished - Feb 1 2009
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this